NY Weed Sales Top $4 Billion Since Market Launched

October 2, 2026

Photo by Marcelo Gonzalez via Pexels.

New York's adult-use cannabis market just crossed a threshold that would have sounded fanciful three years ago: more than $4 billion in cumulative recreational sales since the first licensed dispensaries opened their doors. State regulators announced the milestone alongside a batch of quarterly figures that show the market isn't just surviving, it's accelerating, with each new billion arriving faster than the one before it.

The timing matters. New York built this market on a licensing structure that deliberately prioritizes social and economic equity applicants, a bet that opening the door wider would eventually pay off in broader participation without sacrificing overall growth. Four billion dollars in, dispensary counts keep climbing and so does revenue, but the gains aren't landing evenly across every storefront. That raises an obvious question as the state eyes even bigger numbers by 2028: can this momentum hold, or is it starting to show the strain of uneven growth beneath a headline-grabbing total?

A Record-Setting Third Quarter

Photo by Jopwell via Pexels.

The Office of Cannabis Management's latest tally puts third-quarter 2026 sales at $512.6 million, topping the previous record of $503.7 million set just two quarters earlier in the final stretch of 2025. That's not a one-off spike. Sales climbed from $421 million in the first quarter of 2026 to $479.9 million in the second quarter before hitting that third-quarter high, a steady upward march rather than a volatile bounce. Nine months into the year, cumulative 2026 sales sit at $1.41 billion, already closing in on what some had expected the entire year to produce.

Zoom in on September alone and the contrast with New York's older medical marijuana program becomes stark: roughly $163 million in recreational sales against about $4.8 million in medical sales that same month. That's not a program in decline so much as a program that's been completely overshadowed. Patients who once relied on medical dispensaries for access now have adult-use storefronts on practically every other commercial strip in parts of New York City and upstate population centers, and the purchasing habits of the broader public have simply swamped the smaller, more tightly regulated medical channel. For state budget planners and tax revenue forecasters, that shift toward adult-use is the number that actually moves the needle.

How New York Got to $4 Billion

New York's adult-use cannabis sales rose steadily through 2026, climbing from $421 million in Q1 to $512.6 million by Q3, a 22% increase over three quarters.

New York's recreational market opened in late 2022 under a cloud of skepticism, slowed early on by licensing lawsuits, a scarcity of approved retail locations, and an unlicensed market that had already set up shop on seemingly every corner in Manhattan. It took until December 2024 to cross the first billion dollars in cumulative sales, a pace that looked sluggish compared to how quickly other legal states had scaled. But the trajectory bent upward from there. The second billion came by mid-2025, roughly six months later. The third billion arrived by April 2026, shaving the gap down further. Each milestone has come faster than the last, which is the opposite of what a maturing, plateauing market usually looks like.

John Kagia, the OCM's acting executive director, has put a number on where this is headed: annual sales reaching $4.6 billion by 2028. That's not a modest bump from current levels, it's a projection that assumes New York keeps compounding growth rather than settling into a steady-state market. Some industry analysts have gone further, floating the idea that New York could eventually challenge California as the largest legal cannabis market in the country, a notion that would have seemed absurd given how rocky the state's rollout was in its first eighteen months. Whether that comparison holds up depends heavily on how New York handles the uneven store-level performance showing up in its own data.

More Stores, Uneven Revenue

Photo by Tom Tillhub via Pexels.

Part of the revenue story is simply more stores. The number of adult-use dispensaries recording sales grew from 685 in June 2026 to 735 by September, a meaningful jump in just three months. New shops keep opening, and the overall sales figures keep climbing alongside them.

What's notable is that annualized sales per store haven't dropped much despite all those new entrants, holding at roughly $2.7 million per store. In a market adding dozens of competitors every quarter, that kind of stability suggests underlying demand is still expanding fast enough to absorb new supply rather than just slicing the existing customer base into smaller pieces.

But that average hides a widening split. OCM's own data shows stores in the top revenue quintile pulling in more than four times what stores in the bottom quintile generate. That's not a small gap, and it tells you that geography, timing, and local competition matter enormously in this market. A dispensary that opened early in a high-traffic neighborhood with limited nearby competitors is in a fundamentally different business than one that opened later into a saturated corridor or a lower-traffic location. As licensing continues and more storefronts open, that gap between winners and strugglers is worth watching closely, because it's the clearest early signal of which parts of New York's cannabis retail buildout are actually sustainable.

Licensing and the Equity Mandate

Photo by Marcus Luu via Pexels.

Behind the sales figures sits a licensing structure New York built around equity from the outset. The state currently licenses 1,981 adult-use cannabis businesses across the supply chain: 280 cultivators, 241 distributors, 329 microbusinesses, 582 processors, 548 retail dispensaries, and 370 Conditional Adult-Use Retail Dispensaries, the CAURD category created to get justice-involved applicants and small operators into the market early.

Fifty-six percent of all recreational cannabis licenses issued statewide have gone to applicants meeting the state's social and economic equity criteria, which generally covers people from communities disproportionately affected by past cannabis enforcement, along with disabled veterans, minority- and women-owned businesses, and distressed farmers. That proportion isn't static either; at the Cannabis Control Board's October 1 meeting, 64 percent of newly approved licenses met the equity designation, suggesting the board is leaning even harder into that mandate as the market matures rather than easing off it.

CCB Chair Jessica Garcia, confirmed by the state Senate in mid-2025 after a career as a labor union official, has framed the board's approach as a balancing act: widening access for applicants who were historically locked out of the cannabis trade while still protecting the integrity of a market that state tax revenue and public trust now depend on. It's a mandate that sounds straightforward in a press release and considerably harder to execute when storefronts in the same city are posting revenue four times apart.

What Comes Next for New York's Market

Photo by 2H Media via Unsplash.

Anyone traveling to New York to visit a dispensary, or living elsewhere and wondering about their own state's rules, should confirm current cannabis purchase and possession laws before making any plans. Legal thresholds, age requirements, and what you can legally carry across state lines differ significantly depending on where you are, and New York's licensed market still operates alongside a persistent unlicensed retail scene that shoppers should be aware of when sourcing products. Seedtiva doesn't provide legal advice, so check your local and state regulations directly before assuming anything carries over from one jurisdiction to another.

Looking ahead, the trends already visible in 2026 are likely to keep shaping the market's next phase. More dispensary openings could put additional pressure on that $2.7 million per-store average even as total statewide sales keep rising, especially if new stores continue clustering in already-competitive areas rather than underserved ones. Equity licensing targets, now running above 60 percent for new approvals, will keep determining who gets a seat at the table as the state closes in on Kagia's $4.6 billion projection for 2028.

Whether New York actually narrows the gap with California's cannabis market, as some analysts now suggest is possible, will depend less on raw sales totals and more on whether the state can keep adding profitable stores rather than just more storefronts competing for the same customers.

Four billion dollars is an easy number to put in a headline, but it flattens a market that looks considerably more complicated up close. New York has proven it can generate demand, open stores, and keep growth compounding faster than almost anyone expected back in 2022. What it hasn't proven yet is that its equity-first licensing approach produces businesses built to last, rather than a growing count of storefronts chasing a shrinking share of local foot traffic.

That distinction is going to matter more with every passing quarter. Getting to $4.6 billion by 2028 isn't just a function of opening enough new dispensaries, it's a function of whether the stores already open, especially the equity-licensed ones that make up the majority of recent approvals, can actually turn a profit in a market where the best-performing shops now outearn the weakest by a factor of four. The sales records will keep making headlines. The real test is whether New York's regulators can close that performance gap before it hardens into a permanent two-tier market.